Gimv invests in biopharmaceutical company Complix Gimv invests in biopharmaceutical company Complix Gimv invests in biopharmaceutical company Complix

Gimv invests in biopharmaceutical company Complix


Gimv and Gimv managed Biotech Fonds Vlaanderen invest in Complix, a biopharmaceutical company focused on the discovery and development of novel therapeutics based on its AlphabodiesTM platform. This investment is part of a total Series B equity financing round of EUR 12 million from a syndicate of important life sciences investors, co-led by new investors Gimv and Edmond de Rothschild Investment Partners.

Complix is a biopharmaceutical company developing a pipeline of therapeutics, called AlphabodiesTM, mainly focused on oncology and autoimmunity. Alphabodies are a revolutionary class of protein therapeutics that combine the attractive features of antibodies, including high target specificity and affinity, with the benefits from small chemical drugs such as extreme stability and their capacity to penetrate cells. As a result of these unique features, Alphabodies can tackle a broad range of diseases where treatment options today are limited or non-existent.

Complix is headquartered in Hasselt (Belgium) at the Life Sciences incubator BioVille, and has research facilities in Ghent (Belgium) and in Luxembourg. Since its founding in 2008 Complix has raised a total of EUR 26 million in funding, including the EUR 12 million capital round announced today. This financing round will be used to develop a first set of therapeutic Alphabodies for treatment of cancer and auto-immune indications, and to further develop and validate the company’s unique Alphabody platform.

Mr Patrick Van Beneden, Partner at Gimv, comments: “We are very excited by the Complix opportunity because it perfectly fits in our Health & Care platform strategy for biotech investments. The company combines high-quality and experienced management with a unique technology platform that has the potential to deliver multiple breakthrough products. These are backed by a strong IP position and a focused business plan that we believe will deliver significant, clear shareholder value within a realistic timeframe. This investment confirms Gimv’s continued interest in this market segment.”

Complix is the sixth joint biotech investment in the current portfolio of Gimv and Biotech Fonds Vlaanderen next to Ablynx, Actogenix, Agrosavfe, Multiplicom and Pronota.